Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 177 clinical trials
A Study Evaluating Safety and Tolerability and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

navitoclax is evaluated on the PK, safety, and tolerability of a single dose of celecoxib in participants with myeloproliferative neoplasm (MPN) or chronic myelomonocytic leukemia (CMML).

myelofibrosis
leukemia
bone marrow procedure
polycythemia vera
chronic myelomonocytic leukemia
  • 1 views
  • 27 Jan, 2021
  • 23 locations
Predictive Clinical and Biological Parameters in Acute Leukemia Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015

myeloproliferative disorders by using genomics, genetics and epigenetics, in vitro and in vivo drug sensitivity studies,and translational immonulogy and immunomonitoring studies. HEMATO-BIO primary outcome

remission
leukemia
myelodysplastic syndromes
myeloproliferative disorder
bone marrow procedure
  • 13 views
  • 22 Jan, 2021
  • 1 location
Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia

The hypothesis is that efficient prevention of thrombosis with aspirin at diagnosis becomes less useful once patients have achieved a hematologic response (HR) (modified by amendment 1/03/2017) and/or that this benefit is hampered by an increased hemorrhagic risk especially in elderly patients. Hence, investigator propose a prospective randomized study to …

hydroxyurea
thrombocytosis
aspirin
thrombosis
essential thrombocythemia
  • 1 views
  • 21 Jan, 2021
An Open-Label Multicenter Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

) and AML secondary to myeloproliferative neoplasms (MPN). Participants must be relapsed/refractory (having failed prior therapy) and will be assigned to receive KRT+232 with LDAC or KRT-232 with

refractory acute myeloid leukemia (aml)
decitabine
cancer
cytarabine
  • 2 views
  • 27 Jan, 2021
  • 27 locations
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

This is a Phase 2, multicenter, open-label study to evaluate the efficacy and safety of luspatercept in subjects with MPN-associated myelofibrosis and anemia with and without RBC-transfusion

blood transfusion
luspatercept
myeloproliferative disorder
erythropoietin
anemia
  • 384 views
  • 08 Feb, 2021
  • 26 locations
A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following subjects: Subjects receiving luspatercept on a parent protocol at the time of their transition to the rollover study, who tolerate the protocol-prescribed regimen in the parent trial and, in the opinion of the …

hysterectomy
growth factor
ace-536
cancer
luspatercept
  • 82 views
  • 27 Jan, 2021
  • 125 locations
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

This phase III trial studies response-based chemotherapy in treating newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by …

transient myeloproliferative disorder
leukemia
trisomy
myeloproliferative disorder
daunorubicin
  • 153 views
  • 31 Jan, 2021
  • 139 locations
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Phase 1 Part (Complete): Open-label, sequential dose escalation study of CPI-0610 in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative

myelofibrosis
janus kinase inhibitor
leukemia
myelodysplastic syndromes
myeloproliferative disorder
  • 242 views
  • 04 Feb, 2021
  • 59 locations
Is Clonal Hematopoiesis of Indeterminate Potential Associated With Unprovoked Pulmonary Embolism?

The clonal hematopoiesis of indetermined prognosis (CHIP) has been described as risk factor for juvenile atherosclerosis. Moreover, some of CHIP genes are responsible of myeloproliferative

  • 0 views
  • 04 Feb, 2021
  • 1 location
MPN-RC 118 AVID200 in Myelofibrosis

Increased levels of TGF-1 were detected in serum, plasma and BM and positively correlated with both grade of BMF and extent of leukemic cell infiltration in the marrow. TGF- likely plays a dual role in promoting myelofibrosis and myeloproliferation, both of which are the bone marrow morphologic hallmark of MF. …

thrombocythemia
direct bilirubin
hydroxyurea
thrombocytopenia
polycythemia
  • 0 views
  • 25 Jan, 2021
  • 1 location